Data on Oral Contraceptives Compliance in Non Stop Regimen

Bayer8,416 enrolled

Overview

Adherence to the dosing scheme is the principal element of COC efficiency. On the other hand noncompliance seemed to be an inseparable element of any oral treatment. The aim of the study is to evaluate in everyday practice the relation between dosage errors and indicated factors, potentially influencing the compliance with the dosing scheme.

Study Type

OBSERVATIONAL

Enrollment

8,416

Conditions

Contraception

Interventions

Qlaira or Yaz (BSP products defined as Combined Oral Contraceptive) and Cerazette or Azalia (competitor's products defined as Progestogen Only Pill)DRUG

One tablet per day, orally, 28 tablets per cycle, during three consecutive cycles.

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients at the age of 18-50 requiring contraception, treated with oral contraceptives designed for the scheme 28 pills for 28 days. The decisions would be made at the discretion of the attending physician. Exclusion Criteria: * Patients were not valid for analysis if the initial visit was before start of study in the country (retrospective documentation), or if they did not take oral contraceptives designed for the scheme 28 pills for 28 days.

Locations (1)

Unnamed facility

Many Locations, Poland

Outcomes

Primary Outcomes

The percentage of users showing noncompliant behaviors

Time frame: 3 consecutive cycles (28-days per cycle)

Secondary Outcomes

The characteristics of noncompliant behavior.

Time frame: 3 consecutive cycles (28-days per cycle)

The relation between noncompliant behavior and selected factors.

Time frame: 3 consecutive cycles (28-days per cycle)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.